Business Wire

Hitachi Digital Services Launches HARC Agents to Power Enterprise-Grade Agentic AI

10.9.2025 12:00:00 CEST | Business Wire | Press Release

Share

Today, Hitachi Digital Services unveiled Hitachi Application Reliability Center Agents (HARC Agents), the company’s enterprise platform for trusted Agentic AI. The platform combines a full lifecycle of AI services – from concepting to deployment to optimization – to give customers a vital jump start on mission-critical innovations. A definitive demonstration of advanced automation and human-AI collaboration, HARC Agents enables Hitachi to equip enterprises with complex, scalable AI systems in 30% less time than typically required – significantly reducing time to value.

HARC Agents is comprised of four primary AI resources:

  1. R202.ai: a framework for defining the development and deployment of scalable, enterprise-grade AI workloads in a reliable, responsible, observable, and optimal manner.
  2. HARC for AI: the Hitachi Application Reliability Center hosting professional and managed services that operationalize AI systems; ensuring they are always on, reliable, and cost optimized.
  3. Agent Library (new): a library of pre-built, interconnected agentic AI agents that jump-start more complex agentic AI solution development as well as maximize those solutions’ outputs.
  4. Agent Management System (new): a single dashboard centralizing control of all agentic AI platforms across an enterprise environment; simplifying governance, performance monitoring, and compliance to ensure enterprises can confidently harness the power of AI at scale.

“Simply put, HARC Agents exists to make AI enterprise ready at speed and scale. In today’s unforgiving business environment, only the companies that master AI at full enterprise power will survive and thrive. Generic AI solutions may appear attractive in demonstrations, but they are not built for mission-critical enterprise use and will fail when true pressure is applied,” said Roger Lvin, CEO, Hitachi Digital Services. “Too many technology partners are content to run pilots, chase headlines, and talk theory. Hitachi stands apart by delivering operationalized AI that scales globally, safeguards the enterprise, ensures compliance, mitigates risk, and drives measurable outcomes tied directly to business strategy. The future belongs to those who execute with precision and purpose, and to those who choose partners proven to turn AI into real enterprise value.”

Businesses are embracing AI at an unprecedented rate. Per IDC, global spend on AI technologies is projected to reach $630 billion by 2028 (a CAGR of ~30%), with agentic AI anticipated to represent a majority of those investments. However, research firm Gartner warns that nearly half of agentic AI projects alone will likely be terminated before moving into production by the end of 2027 due to significant cost and complexity coupled with unclear return on investment.

The time it takes to develop custom enterprise-grade AI systems varies dramatically depending on scope. The road to deployment involves numerous intensive steps between ideation and proof of principle through prototyping and production. The engineering work and oversight can be cost-prohibitive and time-consuming. Yet, with the right proven tools, much of it could be automated to alleviate most of that pressure while ensuring a valuable investment return. Which is where AI, specifically agentic AI, proves instrumental.

“Imagine investing tens of millions into an AI system designed to manage sensitive operations, only to discover a year later that it is unreliable, unsecure, and not ready for production. Enterprises cannot afford to stake their future on hype or fragile AI. With HARC Agents, we’ve built a foundation for agentic systems that are not only secure and reliable but deeply integrated across IT and OT environments. Our approach ensures enterprise-wide observability and operational readiness from day one – turning innovation into scalable, sustainable impact,” explained Premkumar Balasubramanian, CTO, Hitachi Digital Services.

Two New HARC Agents Resources Ensure Effective Enterprise AI Accessibility

The new Agent Library is a rich collection of over 200 agents sourced corporate-wide from Hitachi’s group companies, with each company offering distinctive technology competencies. The agents are put to work by Hitachi engineers when developing more complex AI systems. The agents then continue to operate on behalf of the customers when they use those systems. Notably, the agents cross six key domains:

  • Industrial AI (vertical-specific use cases)
  • Operations AI
  • Engineering AI
  • Analytical AI
  • Security AI
  • Cloud AI

The Agent Library will continue to grow as new agents are generated to support internal and external customer project needs.

Simultaneously, Hitachi Digital Services also released today its Agent Management System (AMS). Within the HARC Agents framework, the AMS is a centralized observability and control layer via a single “pane of glass” across a heterogeneous set of agentic platforms such as Copilot Studio, Google Agentspace, Lyzr, Ema, and others. The unified visibility, governance, and lifecycle management of intelligent agents enabled by AMS ultimately ensures secure, scalable, and flexible deployment across enterprise environments.

“Hitachi has long advanced the use of AI across all organizational layers – from executives to frontline engineers – supporting diverse applications such as business risk analysis and predictive maintenance. This is made possible by our decades of experience in building and operating IT systems. The deep domain knowledge embedded in our products and systems is what enables us to successfully deploy Agentic AI. HARC Agents represent a future where AI is not just a tool, but a partner that augments human capabilities and helps solve societal challenges. Through digital innovation, Hitachi is committed to delivering value to everyone and realizing a safe, secure, and sustainable society—a Harmonized Society,” said Jun Abe, Chairman of the Board at Hitachi Digital Services and Executive Vice President of Hitachi, Ltd., General Manager of the Digital Systems & Services Division.

For more information on how HARC Agents can benefit your agentic AI journey, visit www.hitachids.com/service/enterprise-ai.

About Hitachi Digital Services

Hitachi Digital Services, a wholly owned subsidiary of Hitachi, Ltd., is a global systems integrator powering mission-critical platforms with people and technology. We help enterprises build, integrate, and run physical and digital systems with tailored solutions in cloud, data, IoT, and ERP modernization, underpinned by advanced AI. By combining Information Technology and Operational Technology (ITxOT), we drive efficiency, innovation, and growth across industries. With over 110 years of Hitachi Group's engineering and technology leadership, Hitachi Digital Services is powering smarter platforms for a safer, more sustainable future. For more information on Hitachi Digital Services, please visit the company's website at www.hitachids.com.

About Hitachi, Ltd.

Through its Social Innovation Business (SIB) that brings together IT, OT (Operational Technology) and products, Hitachi contributes to a harmonized society where the environment, wellbeing, and economic growth are in balance. Hitachi operates globally in four sectors – Digital Systems & Services, Energy, Mobility, and Connective Industries – and the Strategic SIB Business Unit for new growth businesses. With Lumada at its core, Hitachi generates value from integrating data, technology and domain knowledge to solve customer and social challenges. Revenues for FY2024 (ended March 31, 2025) totaled 9,783.3 billion yen, with 618 consolidated subsidiaries and approximately 280,000 employees worldwide. Visit us at www.hitachi.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250910745034/en/

Contacts

Hitachi Digital Services
Patrick Corcoran
Head of Market Enablement and External Relations
patrick.corcoran@hitachids.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 13:30:00 CEST | Press Release

Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European Society for Medical Oncology (ESMO) Congress, showed the study met its dual primary endpoints of overall survival (OS) and progression-free survival (PFS). Gastric cancer is a leading cause of cancer-related death worldwide, and outcomes are particularly poor once the disease is advanced.1 Because treatment options are limited for people whose cancer continues to progress after multiple therapies, there is a significant need for new targeted therapies.2 CLDN18.2, a protein found at abnormally high levels on the surface of certain cancer cells, has emerged as a key biomarke

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye